Azmain Alamgir, a Ph.D. graduate from Cornell University and now a postdoctoral researcher at MIT, stands in a lab thousands of miles from Ithaca, watching a tiny vial of lipid nanoparticles carry a powerful cargo: full-length therapeutic antibodies, cloaked and ready to slip past cellular defenses. This isn’t science fiction—it’s a breakthrough published June 23 in the Proceedings of the National Academy of Sciences that could reshape how we treat diseases like cancer, Parkinson’s, and acute lung injury. For decades, antibodies—despite their success in treating everything from autoimmune disorders to tumors—have been largely confined to targets outside cells. Their size and charge make crossing the cell membrane nearly impossible. But Alamgir and his collaborators, including Chris Alabi and Matt DeLisa at Cornell, have cracked the code.
Their method hinges on a chemical trick: anionic cloaking. By attaching a negatively charged sulfonate group called SL4 to IgG antibodies, the team reverses their surface charge, allowing them to bind electrostatically to positively charged lipid nanoparticles—specifically MC3 LNPs, the same delivery vehicles used in mRNA vaccines. Once inside the cell, the antibodies shed their cloak and go to work on intracellular targets, precisely where many disease mechanisms hide.
The implications were tested across continents and conditions. In Israel, Avi Schroeder’s team at the Technion-Israel Institute of Technology used the cloaking protocol to deliver anti-alpha-synuclein antibodies into brain cells, aiming to disrupt the protein aggregates that drive Parkinson’s disease. Meanwhile, back at Cornell, Alamgir’s group applied the same platform to deliver anti-NF-kB antibodies in a mouse model of acute lung injury, significantly reducing inflammation. This dual success—on two vastly different diseases, in two different organs, and validated independently abroad—marks a turning point. It’s no longer just a lab curiosity; it’s a reproducible, organ-targeted delivery system with real therapeutic impact.
The team has already launched Cloak Bio, a startup aimed at accelerating the platform’s clinical translation. But perhaps the most exciting part is what comes next—not just in their hands, but in the hands of scientists worldwide. As Alabi puts it, "We are excited to get this material into the hands of other people and see what they do with it." With a technology that can now deliver clinically validated antibodies inside cells, the next wave of biologic therapies may finally reach the places they’re needed most.